Trial Profile

Airway Remodeling Changes Induced by Mepolizumab in Severe Eosinophil Asthma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mepolizumab (Primary)
Indications Asthma
Focus Pharmacodynamics; Therapeutic Use
Acronyms REMOMEPO

Most Recent Events

22 May 2024 Results (n=23) reporting efficacy of mepolizumab in eosinophilic asthma presented at the 120th International Conference of the American Thoracic Society
19 Jan 2023 Status changed from recruiting to completed.
07 Jun 2021 Planned End Date changed from 1 Oct 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com